𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Nonlinear pharmacokinetics of TAK-044, a new endothelin antagonist, in rats

✍ Scribed by Toshiyuki Takeuchi; Yoshihiko Tagawa; Kiyoshi Hagihara; Yoshihiro Maeshiba; Kenji Yamashita; Ryoichi Tsukuda; Yoshinobu Yoshimura

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
147 KB
Volume
22
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Possible factor for nonlinear pharmacoki
Possible factor for nonlinear pharmacokinetics of TAK-603, a new antirheumatic agent, in rats
✍ Yoshihiko Tagawa; Kiyoshi Miwa; Kenji Yamashita; Ryoichi Tsukuda; Yoshinobu Yosh πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 158 KB

A new antirheumatic, TAK-603, shows nonlinear pharmacokinetics in both animals and humans. To elucidate the mechanism of these nonlinear pharmacokinetics, in vivo and in vitro metabolism of 14 C-labeled TAK-603 ([ 14 C]TAK-603) was studied using rats as these resemble humans in their metabolic profi

Hepatoprotective effect of the endotheli
Hepatoprotective effect of the endothelin receptor antagonist TAK-044 against ischemia-reperfusion injury in the canine liver
✍ Y Kitayama; N Yamanaka; E Kawamura; N Kuroda; E Okamoto πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 423 KB πŸ‘ 1 views

The present study was designed to investigate if TAKparallel with a decrease in hepatic arterial and portal blood 044, a novel endothelin (ET) ET A /ET B receptor antagoflow. These pathological changes were reversed after ET-1 nist, inhibits ischemia-reperfusion liver injury. The iniinfusion was com

Multiple-dose pharmacokinetics of the ne
Multiple-dose pharmacokinetics of the new H1-receptor antagonist tazifylline in healthy volunteers
✍ R. Bruno; I. Jullien; J. Auger; A. Iliadis; R. Dow; J. McEwen; J. P. Cano; H. Pi πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 221 KB πŸ‘ 2 views

The multiple-dose pharmacokinetics of the new HI-receptor antagonist, tazifylline, were investigated in healthy volunteers. From single-dose data, tazifylline appeared to be rapidly absorbed (median tm, of 0.6 h) and eliminated (t% 1.0 f 0.2 h). However, plasma levels measured on days 3 and 8 of the